Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nature13807 http://scihub22266oqcxt.onion/10.1038/nature13807 C4236859!4236859 !25274301     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25274301 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25274301 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Nature 2014 ; 514 (7523 ): 450-4 Nephropedia Template TP {{tp|p=25274301 |t=2014. Pulmonary macrophage transplantation therapy |pdf=|usr=}}{{25274301 }} gab.com Text Pulmonary macrophage transplantation therapy JO: Nature http://www.kidney.de/pget.php?&tw=1&pmid=25274301 #FOAvip Bone-marrow transplantation is an effective cell therapy but requires myeloablation, which increases infection risk and mortality. Recent lineage-tracing studies documenting that resident macrophage populations self-maintain independently of haematological progenitors prompted us to consider organ-targeted, cell-specific therapy. Here, using granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor-?-deficient (Csf2rb(-/-)) mice that develop a myeloid cell disorder identical to hereditary pulmonary alveolar proteinosis (hPAP) in children with CSF2RA or CSF2RB mutations, we show that pulmonary macrophage transplantation (PMT) of either wild-type or Csf2rb-gene-corrected macrophages without myeloablation was safe and well-tolerated and that one administration corrected the lung disease, secondary systemic manifestations and normalized disease-related biomarkers, and prevented disease-specific mortality. PMT-derived alveolar macrophages persisted for at least one year as did therapeutic effects. Our findings identify mechanisms regulating alveolar macrophage population size in health and disease, indicate that GM-CSF is required for phenotypic determination of alveolar macrophages, and support translation of PMT as the first specific therapy for children with hPAP. Twit Text FOAVip Pulmonary macrophage transplantation therapy ????Nature http://www.kidney.de/pget.php?&tw=1&pmid=25274301 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25274301 #FOAvip English Wikipedia <ref>{{Cite pmid|25274301 }}</ref> Pulmonary macrophage transplantation therapy #MMPMID25274301 Suzuki T ; Arumugam P ; Sakagami T ; Lachmann N ; Chalk C ; Sallese A ; Abe S ; Trapnell C ; Carey B ; Moritz T ; Malik P ; Lutzko C ; Wood RE ; Trapnell BC Nature 2014[Oct]; 514 (7523 ): 450-4 PMID25274301 show ga Bone-marrow transplantation is an effective cell therapy but requires myeloablation, which increases infection risk and mortality. Recent lineage-tracing studies documenting that resident macrophage populations self-maintain independently of haematological progenitors prompted us to consider organ-targeted, cell-specific therapy. Here, using granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor-?-deficient (Csf2rb(-/-)) mice that develop a myeloid cell disorder identical to hereditary pulmonary alveolar proteinosis (hPAP) in children with CSF2RA or CSF2RB mutations, we show that pulmonary macrophage transplantation (PMT) of either wild-type or Csf2rb-gene-corrected macrophages without myeloablation was safe and well-tolerated and that one administration corrected the lung disease, secondary systemic manifestations and normalized disease-related biomarkers, and prevented disease-specific mortality. PMT-derived alveolar macrophages persisted for at least one year as did therapeutic effects. Our findings identify mechanisms regulating alveolar macrophage population size in health and disease, indicate that GM-CSF is required for phenotypic determination of alveolar macrophages, and support translation of PMT as the first specific therapy for children with hPAP. |*Cell Transplantation [MESH] |*Genetic Therapy [MESH] |Animals [MESH] |Cell Separation [MESH] |Cytokine Receptor Common beta Subunit/deficiency/*genetics [MESH] |Female [MESH] |Lung/*cytology/metabolism/pathology [MESH] |Macrophages, Alveolar/*metabolism/*transplantation [MESH] |Male [MESH] |Mice [MESH] |Oligonucleotide Array Sequence Analysis [MESH] |Phenotype [MESH] |Pulmonary Alveolar Proteinosis/genetics/pathology/*therapy [MESH]Pulmonary macrophage transplantation therapy (epmc).pdf DeepDyve Pubget Overpricing